6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A variety of distinct and redundant mechanisms support tumour propagation and survival. Tumour parenchyma consists of a variety of geographically diverse cells with varying genetic expression among subclonal populations. Additionally, the solid tumour microenvironment consists of a dense network of stromal, vascular and immune cells altered by a number of mechanisms not only to tolerate but often to enhance cancer growth. The limited spectrum of chimaeric antigen receptor (CAR) T-cell specificity in the face of this dynamic landscape is one of the greatest challenges facing CAR T-cell therapy for solid tumours. Thus targeting multiple cancer-specific markers simultaneously could result in improved efficacy by broadening the therapeutic reach to include multiple subclonal populations of the tumour parenchyma as well as elements of the tumour microenvironment. Over the last 10 years, we and others have developed multiplex platforms that target the tumour profile rather than single tumour-restricted antigens. These platforms introduce a new dimension that may be key to the successful development of T-cell therapies for solid tumours and to the mitigation of relapses due to antigen escape.

          Related collections

          Author and article information

          Journal
          Biochem. Soc. Trans.
          Biochemical Society transactions
          Portland Press Ltd.
          1470-8752
          0300-5127
          Apr 15 2016
          : 44
          : 2
          Affiliations
          [1 ] Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX 77030, U.S.A. Texas Children's Cancer and Hematology Centers, Houston, TX 77030, U.S.A. Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, U.S.A. Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, U.S.A. sanavai@txch.org nahmed@bcm.edu).
          Article
          BST20150266
          10.1042/BST20150266
          27068945
          0dd83fc2-ed1f-44a0-ac6e-91ec51074266
          History

          tumour heterogeneity,antigen escape,bispecific,chimaeric antigen receptor,multispecific,tandem chimaeric antigen receptor (TanCAR)

          Comments

          Comment on this article